Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

6.8%

3 terminated out of 44 trials

Success Rate

88.0%

+1.5% vs benchmark

Late-Stage Pipeline

36%

16 trials in Phase 3/4

Results Transparency

41%

9 of 22 completed with results

Key Signals

9 with results88% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (5)
Early P 1 (2)
P 1 (9)
P 2 (8)
P 3 (5)
P 4 (11)

Trial Status

Completed22
Unknown8
Recruiting5
Active Not Recruiting4
Terminated3
Withdrawn1

Trial Success Rate

88.0%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT06462196Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT07210463Phase 3Active Not Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT06511908Phase 2Recruiting

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT05288166Phase 3Active Not Recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT04365101Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT07122193Phase 3Active Not Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT06606587Not ApplicableCompletedPrimary

Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia

NCT05615948Phase 4Completed

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT06535568Not ApplicableRecruiting

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT04289142Phase 4Recruiting

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

NCT07167550Phase 3Recruiting

The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke

NCT02242968Completed

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT05284097Phase 2Completed

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT03646292Phase 4Completed

Antidiabetic Drugs for Steatotic Liver Disease

NCT03964350Early Phase 1Completed

Behavior Brain Responses

NCT04310592Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

NCT04045301Phase 2Active Not Recruiting

Omalizumab to Accelerate a Symptom-driven Multi-food OIT

NCT05794503Phase 4Completed

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05657860Phase 4Completed

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05321602Phase 1Completed

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Scroll to load more

Research Network

Activity Timeline